Northwestern Team Develops Implantable "Living Pharmacy" Device That Produces Multiple Drugs Simultaneously
Key Insights
Northwestern University researchers have developed HOBIT, an implantable device containing engineered cells that continuously produce multiple biologic drugs inside the body, including anti-HIV (search) antibodies, diabetes treatments, and appetite-regulating hormones.
The device integrates oxygen-producing bioelectronics to overcome the critical challenge of cell survival in implants, achieving cell densities six times higher than conventional approaches and maintaining 65% cell viability after 30 days.
In animal studies, the gum-sized wireless device successfully delivered sustained levels of three different biologics with varying half-lives for 30 days, while control devices without oxygenation failed by day seven.
A multi-institutional research team led by Northwestern University has achieved a significant breakthrough in implantable drug delivery systems, developing a wireless device that functions as an internal "living pharmacy" capable of producing multiple biologic medicines simultaneously inside the body.
The device, called HOBIT (hybrid oxygenation bioelectronics system for implanted therapy), represents a major advance toward treating chronic diseases with a single, long-lasting implantable therapy. Published in Device, a Cell Press journal, the study demonstrates successful production of three different biologics - an anti-HIV antibody (search), a GLP-1-like peptide (search) for type 2 diabetes (search) treatment, and leptin, a hormone regulating appetite and metabolism.
Solving the Oxygen Challenge
The key innovation addresses a fundamental barrier that has limited previous implantable cell therapy approaches: oxygen supply. When engineered cells are densely packed inside an implant, they compete for limited oxygen, leading to widespread cell death and reduced drug production capacity.
"We are producing oxygen directly where the cells need it," said Jonathan Rivnay, co-principal investigator and Jerome B. Cohen Professor of Engineering at Northwestern. "That allows us to support much higher cell densities in a much smaller space. Cell densities in HOBIT were roughly six times higher than conventional unoxygenated encapsulation approaches."
The HOBIT system integrates three primary components: a cell chamber containing genetically engineered therapeutic cells, a miniature oxygen generator that splits water molecules electrochemically, and electronics with a battery for regulating oxygen production and wireless communication with external devices.
Sustained Multi-Drug Delivery
In 30-day animal studies using rats, the researchers demonstrated the device's ability to maintain therapeutic drug levels across biologics with different half-lives. Animals receiving oxygenated implants showed sustained blood levels of all three biologics throughout the study period, while control devices without oxygenation failed to maintain detectable levels of shorter half-life biologics by day seven.
The results showed dramatic improvements in cell survival. At the study's conclusion, approximately 65% of cells in oxygenated devices remained viable compared to only 20% in control devices without oxygen supplementation.
"Traditional biologic drugs often have very different half-lives, so maintaining stable levels of multiple therapies can be challenging," Rivnay explained. "Because our implanted 'cell factories' continuously produce these biologics, keeping the cells alive with our oxygenation technology allows us to sustain steady levels multiple different therapeutics at once."
Clinical Implications and Future Development
The device, roughly the size of a folded stick of gum, shields therapeutic cells from the body's immune system while providing essential oxygen and nutrients for sustained drug production over several weeks. This approach could potentially eliminate the burden of daily medication management for patients with chronic conditions.
The research builds on the team's 2023 Nature Communications study that first demonstrated local oxygen generation for implanted therapeutic cells. The current work represents a significant advancement by integrating the oxygen-generation technology into a fully implantable, wireless system designed for long-term therapeutic applications.
"We're beginning to see how bioelectronics and cell therapy can work together in a single platform," Rivnay said. "As these technologies continue to develop, devices like this could eventually act as programmable drug factories inside the body - delivering complex therapies in ways that simply aren't possible today."
The research team, which includes collaborators from Rice University and Carnegie Mellon University, plans to advance the technology through testing in larger animal models and explore disease-specific applications, including therapies based on transplanted pancreatic cells. The study was supported by Breakthrough T1D (search) and the U.S. Defense Advanced Research Projects Agency (search).